Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Pharmacological modulation of vascular ageing, A review from VascAgeNet

  • Roth, L.|||0000-0003-1397-1810
  • Dogan, S.|||0000-0002-7762-8109
  • Tuna, B.G.
  • Aranyi, T.
  • Benitez, Sonia|||0000-0003-3565-0743
  • Borrell-Pages, Maria|||0000-0002-1759-9756
  • Bozaykut, P.
  • De Meyer, G.R.Y.
  • Duca, L.
  • Durmus, N.
  • Fonseca, D.
  • Fraenkel, E.|||0000-0002-3902-5067
  • Gillery, P.
  • Giudici, A.
  • Jaisson, S.
  • Johansson, M.
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Lucas-Herald, A.K.
  • Martinet, W.
  • Maurice, P.
  • McDonnell, B.J.
  • Ozbek, E.N.
  • Pucci, G.
  • Pugh, C.J.A.|||0000-0002-5932-4793
  • Rochfort, K.D.|||0000-0003-1198-5952
  • Roks, A.J.M.
  • Rotllan, Noemi|||0000-0002-0587-8045
  • Shadiow, J.|||0000-0003-0293-6753
  • Sohrabi, Y.
  • Spronck, B.
  • Szeri, F.
  • Terentes-Printzios, D.
  • Tunc Aydin, E.
  • Tura-Ceide, O.
  • Ucar, E.
  • Yetik-Anacak, G.
Vascular ageing, characterized by structural and functional changes in blood vessels of which arterial stiffness and endothelial dysfunction are key components, is associated with increased risk of cardiovascular and other age-related diseases. As the global population continues to age, understanding the underlying mechanisms and developing effective therapeutic interventions to mitigate vascular ageing becomes crucial for improving cardiovascular health outcomes. Therefore, this review provides an overview of the current knowledge on pharmacological modulation of vascular ageing, highlighting key strategies and promising therapeutic targets. Several molecular pathways have been identified as central players in vascular ageing, including oxidative stress and inflammation, the renin-angiotensin-aldosterone system, cellular senescence, macroautophagy, extracellular matrix remodelling, calcification, and gasotransmitter-related signalling. Pharmacological and dietary interventions targeting these pathways have shown potential in ameliorating age-related vascular changes. Nevertheless, the development and application of drugs targeting vascular ageing is complicated by various inherent challenges and limitations, such as certain preclinical methodological considerations, interactions with exercise training and sex/gender-related differences, which should be taken into account. Overall, pharmacological modulation of endothelial dysfunction and arterial stiffness as hallmarks of vascular ageing, holds great promise for improving cardiovascular health in the ageing population. Nonetheless, further research is needed to fully elucidate the underlying mechanisms and optimize the efficacy and safety of these interventions for clinical translation.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Diabetic microvascular disease in non-classical beds, the hidden impact beyond the retina, the kidney, and the peripheral nerves

  • Mauricio, Didac|||0000-0002-2868-0250
  • Gratacòs, Mònica|||0000-0001-7304-7289
  • Franch-Nadal, Josep|||0000-0002-5175-1555
Diabetes microangiopathy, a hallmark complication of diabetes, is characterised by structural and functional abnormalities within the intricate network of microvessels beyond well-known and documented target organs, i.e., the retina, kidney, and peripheral nerves. Indeed, an intact microvascular bed is crucial for preserving each organ's specific functions and achieving physiological balance to meet their respective metabolic demands. Therefore, diabetes-related microvascular dysfunction leads to widespread multiorgan consequences in still-overlooked non-traditional target organs such as the brain, the lung, the bone tissue, the skin, the arterial wall, the heart, or the musculoskeletal system. All these organs are vulnerable to the physiopathological mechanisms that cause microvascular damage in diabetes (i.e., hyperglycaemia-induced oxidative stress, inflammation, and endothelial dysfunction) and collectively contribute to abnormalities in the microvessels' structure and function, compromising blood flow and tissue perfusion. However, the microcirculatory networks differ between organs due to variations in haemodynamic, vascular architecture, and affected cells, resulting in a spectrum of clinical presentations. The aim of this review is to focus on the multifaceted nature of microvascular impairment in diabetes through available evidence of specific consequences in often overlooked organs. A better understanding of diabetes microangiopathy in non-target organs provides a broader perspective on the systemic nature of the disease, underscoring the importance of recognising the comprehensive range of complications beyond the classic target sites.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

NAD+ Precursors and Intestinal Inflammation, Therapeutic Insights Involving Gut Microbiota

  • Niño-Narvión, Julia|||0000-0001-6514-0731
  • Rojo López, Marina Idalia|||0000-0001-6748-3156
  • Martinez-Santos, Patricia
  • Rossell, Joana|||0000-0003-1500-6379
  • Ruiz-Alcaraz, Antonio J.|||0000-0001-6913-0610
  • Alonso Pedrol, Núria|||0000-0001-9687-8050
  • Ramos-Molina, Bruno|||0000-0001-6804-5449
  • Mauricio, Didac|||0000-0002-2868-0250
  • Julve i Gil, Josep|||0000-0002-6531-2246
The oxidized form of nicotinamide adenine dinucleotide (NAD+) is a critical metabolite for living cells. NAD+ may act either as a cofactor for many cellular reactions as well as a coenzyme for different NAD+-consuming enzymes involved in the physiological homeostasis of different organs and systems. In mammals, NAD+ is synthesized from either tryptophan or other vitamin B3 intermediates that act as NAD+ precursors. Recent research suggests that NAD+ precursors play a crucial role in maintaining the integrity of the gut barrier. Indeed, its deficiency has been associated with enhanced gut inflammation and leakage, and dysbiosis. Conversely, NAD+-increasing therapies may confer protection against intestinal inflammation in experimental conditions and human patients, with accumulating evidence indicating that such favorable effects could be, at least in part, mediated by concomitant changes in the composition of intestinal microbiota. However, the mechanisms by which NAD+-based treatments affect the microbiota are still poorly understood. In this context, we have focused specifically on the impact of NAD+ deficiency on intestinal inflammation and dysbiosis in animal and human models. We have further explored the relationship between NAD+ and improved host intestinal metabolism and immunity and the composition of microbiota in vivo. Overall, this comprehensive review aims to provide a new perspective on the effect of NAD+-increasing strategies on host intestinal physiology.